The drug was approved for patients with TGCT with severe morbidity or functional limitations that has not improved with surgery. Turalio is only available through the Risk Evaluation and Mitigation Strategy Program. Approval was based on data from a multicenter international clinical trial of 120 patients. After 25 weeks, patients who received Turalio had a...